Despite recent advances, current knowledge of respiratory muscle development, aging and disease remains incomplete. For example, the molecular and functional properties of muscle stem cells are not worked out, mechanisms of muscle injury and aging are not fully understood, and the role of apoptosis in muscle cell death remains unclear. The proposed experiments are designed to extend knowledge in these key areas of muscle molecular physiology.
Under Aims 1 and 2, the investigators will determine whether targeted alterations of cell death pathways can inhibit either the myofiber death that occurs in disease or the muscle phenotype changes that occur during aging. Apoptotic nuclei are found in dystrophic muscles, but the importance of apoptosis in dystrophic myofiber death is unclear. Muscle fibers are also lost by unknown mechanisms during aging. By analyzing dystrophic or aged myofibers that overexpress Bcl-2 or lack Bax, the investigators will determine if inhibition of apoptosis will inhibit dystrophic myofiber death or age-related changes in muscle phenotype. The results could potentially lead to therapies of myofiber death in disease and aging based on alteration of cell death pathways.
Under Aims 3 and 4, the investigators will determine if the small subset of Sca-1+ and Bcl-2+ muscle cells have the properties of muscle stem cells and how Bcl-2 may function to regulate apoptosis and cell cycle progression in muscle cells. Sca-1 and Bcl-2 are expressed by a limited subset of mononuclear muscle cells, and these cells are at an early stage of myogenesis. The investigators will purify Sca-2+ cells (with anti-Sca-1 immunobeads) and Bcl-2+ cells that have been modified to express selectable markers (with immunobeads or FACS) and they will determine how the functions of these rare early myogenic cells differ from the functions of the more numerous myoblasts that are at a later stage of myogenesis. The identification and characterization of muscle stem cells is central to increasing the understanding of myogenesis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL064641-06
Application #
6767601
Study Section
Respiratory and Applied Physiology Study Section (RAP)
Program Officer
Berberich, Mary Anne
Project Start
2000-07-01
Project End
2006-04-14
Budget Start
2004-07-01
Budget End
2006-04-14
Support Year
6
Fiscal Year
2004
Total Cost
$472,950
Indirect Cost
Name
Boston Biomedical Research Institute
Department
Type
DUNS #
058893371
City
Watertown
State
MA
Country
United States
Zip Code
02472
Jones, Takako Iida; Chen, Jennifer C J; Rahimov, Fedik et al. (2012) Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum Mol Genet 21:4419-30
Homma, Sachiko; Chen, Jennifer C J; Rahimov, Fedik et al. (2012) A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. Eur J Hum Genet 20:404-10
Homma, Sachiko; Beermann, Mary Lou; Miller, Jeffrey Boone (2011) Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-?2-deficient mouse model of congenital muscular dystrophy. Hum Mol Genet 20:2662-72
Beermann, Mary Lou; Ardelt, Magdalena; Girgenrath, Mahasweta et al. (2010) Prdm1 (Blimp-1) and the expression of fast and slow myosin heavy chain isoforms during avian myogenesis in vitro. PLoS One 5:e9951
Vishnudas, Vivek K; Miller, Jeffrey Boone (2009) Ku70 regulates Bax-mediated pathogenesis in laminin-alpha2-deficient human muscle cells and mouse models of congenital muscular dystrophy. Hum Mol Genet 18:4467-77
Girgenrath, Mahasweta; Beermann, Mary Lou; Vishnudas, Vivek K et al. (2009) Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann Neurol 65:47-56
Miller, Jeffrey B; Girgenrath, Mahasweta (2006) The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy. Trends Mol Med 12:279-86
Girgenrath, Mahasweta; Weng, Shawn; Kostek, Christine A et al. (2006) TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 25:5826-39
Nowak, Jonathan A; Malowitz, Jonathan; Girgenrath, Mahasweta et al. (2004) Immortalization of mouse myogenic cells can occur without loss of p16INK4a, p19ARF, or p53 and is accelerated by inactivation of Bax. BMC Cell Biol 5:1
Pavlath, Grace K; Dominov, Janice A; Kegley, Kristy M et al. (2003) Regeneration of transgenic skeletal muscles with altered timing of expression of the basic helix-loop-helix muscle regulatory factor MRF4. Am J Pathol 162:1685-91

Showing the most recent 10 out of 11 publications